Live news related to NANOBIOTIX stock (FR0011341205): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The French biotech company reaches a new all-time high of €41.52 during the session, surpassing the previous peak of €40.52. The stock is trading at €…
The French biotech company experienced another euphoric session this Thursday, May 7. The stock reached an all-time high of €38.40 intraday, before se…
The stock of the French biotech company sharply accelerates at midday, driven by a very dynamic Parisian market and the response to the amendment appr…
The stock of the French biotech firm rallies during Tuesday's session, following the announcement of the Phase 3 NANORAY-312 trial. The share price is…
Nanobiotix announced on Monday the FDA's acceptance of an amendment to the global Phase 3 NANORAY-312 study protocol on head and neck cancer. This ame…
Nanobiotix shares fell by 4.32% to €27.48 mid-session on Monday, after closing at €28.72. The decline is part of a broader dip, with the CAC 40 down b…
Nanobiotix drops 0.99% to €28.06 in late afternoon trading on Euronext Paris, amidst a 0.34% decline in the CAC 40. The oncological nanomedicine biote…
Nanobiotix stands out in Thursday's Paris trading session with a 5.48% increase to 28.50 euros. The French medtech company specializing in nanomedicin…
Nanobiotix significantly advanced this Wednesday, driven by a notable upward momentum over recent months. The stock of the French biotech specializing…
Nanobiotix announced on Monday the presentation of new preclinical data evaluating its nanoprimer platform combined with DNA immunotherapies delivered…
